Evaluation of Cardiac Biomarkers in Chronic Heart Failure

Chronic heart failure (CHF) is a global health burden associated with significant morbidity and mortality. Cardiac biomarkers play a crucial role in the diagnosis, prognosis, and management of CHF. This study aims to evaluate the levels of key cardiac biomarkers—particularly B-type Natriuretic Peptide (BNP), N-terminal proBNP (NT-proBNP), Troponins (cTnI and cTnT), and Galectin-3—in patients with chronic heart failure and to correlate these levels with disease severity. A cross-sectional analysis of 50 CHF patients was performed. Biomarker levels were measured using ELISA and chemiluminescence assays. Statistical correlation was made with clinical data including NYHA classification, echocardiographic parameters, and comorbidities. The study reinforces the clinical utility of biomarkers in the stratification and therapeutic monitoring of CHF. Chronic Heart Failure (CHF) is a complex clinical syndrome characterized by the heart's inability to pump sufficient blood to meet the metabolic demands of the body. It represents a major public health challenge globally, leading to high rates of hospitalization, reduced quality of life, and increased mortality. The early and accurate assessment of disease severity and prognosis is essential for timely intervention and better management. In recent years, cardiac biomarkers have emerged as indispensable tools not only in diagnosing CHF but also in monitoring its progression and guiding therapy.This study aims to evaluate and correlate the levels of selected cardiac biomarkers—namely B-type Natriuretic Peptide (BNP), N-terminal pro-B-type Natriuretic Peptide (NT-proBNP), Cardiac Troponin I (cTnI), and Galectin-3—in patients diagnosed with chronic heart failure. The objective was to analyze the relationship of these biomarkers with clinical severity (NYHA class), echocardiographic parameters (e.g., LVEF), and other comorbid conditions. A cross-sectional observational study was conducted on 50 CHF patients, using ELISA methods for biomarker estimation. The findings demonstrate a significant correlation between elevated levels of NT-proBNP and Galectin-3 with worsening NYHA functional class and reduced left ventricular ejection fraction, reinforcing their prognostic value. Troponin I, although traditionally associated with acute coronary syndromes, was found to be elevated in a considerable proportion of CHF patients, suggesting ongoing subclinical myocardial injury. Galectin-3, a marker of fibrosis and inflammation, showed promise in identifying patients at higher risk of disease progression. This study concludes that cardiac biomarkers provide crucial diagnostic and prognostic information in chronic heart failure. Incorporating biomarker profiling into routine clinical assessment may enhance individualized care, aid in risk stratification, and improve therapeutic outcomes. The integration of a multimarker strategy could potentially refine the clinical approach and enable earlier identification of deteriorating cardiac function in CHF patients. Keywords: Chronic Heart Failure, Cardiac Biomarkers, NT-proBNP, Troponins, Galectin-3, NYHA Classification, Prognosis